As convinced as I am that cabo will be approved and will become a viable player in the cancer treatment market, I have been so very burnt before...Why, oh why, with such convincing evidence, is the decision going down to the VERY wire?
You'll be fine. ACAD was the real edge of the couch stock this morning....50/50 chance could've gone either way big time. Less risk here, but also less reward. I'm happy either way, this is play money now.
"Why, oh why, with such convincing evidence, is the decision going down to the VERY wire?"
The evidence is not the problem, the FDA's decision to go to the wire is more a function of the fact that the need is being met by the enhanced availability program, and the FDA is aware that Exelixis is chomping at the bit to apply for permission to sell cabo "off-label" and for insurance companies to cover the cost. The FDA is holding up the approval to show EXEL who the boss is.
The FDA flexed it's muscles when they disallowed the SPA a year ago and there seems to be someone at the FDA that has a problem with EXEL and or it's management. It may sound like some sort of conspiracy theory but I believe that where there is smoke there is sometimes a fire.
Welcome to Biotech investing. We all know were supposed to buy a number of companies in this volatile industry rather than loading up on just one or two companies, but we do anyway. I think patience is key to this game. Exel looks like a great spec to me